NAGIOS: RODERIC FUNCIONANDO

Combined kinetic analysis of SARS-CoV-2 RNAemia, N-antigenemia and virus-specific antibodies in critically ill adult COVID-19 patients

Repositori DSpace/Manakin

IMPORTANT: Aquest repositori està en una versió antiga des del 3/12/2023. La nova instal.lació está en https://roderic.uv.es/

Combined kinetic analysis of SARS-CoV-2 RNAemia, N-antigenemia and virus-specific antibodies in critically ill adult COVID-19 patients

dc.contributor.author	Costa, Rosa
dc.contributor.author	Alberola Enguídanos, Juan
dc.contributor.author	Olea, Beatriz
dc.contributor.author	Gozalbo Rovira, Roberto Vicente
dc.contributor.author	Giménez Quiles, Estela Berenice
dc.contributor.author	Cuevas Ferrando, Enric
dc.contributor.author	Torres, Ignacio
dc.contributor.author	Albert Vicent, Eliseo Alejandro
dc.contributor.author	Carbonell, Nieves
dc.contributor.author	Ferreres, José
dc.contributor.author	Sánchez, Gloria
dc.contributor.author	Rodríguez Díaz, Jesús
dc.contributor.author	Blasco, María Luisa
dc.contributor.author	Navarro Ortega, David
dc.date.accessioned	2022-06-15T17:53:10Z
dc.date.available	2022-06-15T17:53:10Z
dc.date.issued	2022
dc.identifier.citation	Costa, Rosa Alberola Enguídanos, Juan Olea, Beatriz Gozalbo Rovira, Roberto Vicente Giménez Quiles, Estela Berenice Cuevas-Ferrando, Enric Torres, Ignacio Albert Vicent, Eliseo Alejandro Carbonell, Nieves Ferreres, José Sánchez, Gloria Rodríguez Díaz, Jesús Blasco, María Luisa Navarro Ortega, David 2022 Combined kinetic analysis of SARS-CoV-2 RNAemia, N-antigenemia and virus-specific antibodies in critically ill adult COVID-19 patients Scientific Reports 12 8273
dc.identifier.uri	https://hdl.handle.net/10550/83168
dc.description.abstract	Combined kinetic analysis of plasma SARS‐CoV‐2 RNAemia, Nucleocapsid (N)‐antigenemia and virus‐specific antibodies may help ascertain the role of antibodies in preventing virus dissemination in COVID‐19 patients. We performed this analysis in a cohort of 71 consecutive critically ill COVID‐19 patients (49 male; median age, 65 years) using RT‐PCR assay, lateral flow immunochromatography method and receptor binding domain (RBD) and N‐based immunoassays. A total of 338 plasma specimens collected at a median of 12 days after symptoms onset were available for analyses. SARS‐ CoV‐2 RNAemia and N‐antigenemia were detected in 37 and 43 specimens from 26 (36.5%) and 30 (42.2%) patients, respectively. Free RNA was the main biological form of SARS‐CoV‐2 found in plasma. The detection rate for both viral components was associated with viral load at the upper respiratory tract. Median time to SARS‐CoV‐2‐RBD antibody detection was 14 days (range, 4-38) from onset of symptoms. Decreasing antibody levels were observed in parallel to increasing levels of both RNAemia and N‐antigenemia, yet overall a fairly modest inverse correlation (Rho = −0.35; P < 0.001) was seen between virus RNAemia and SARS‐CoV‐2‐RBD antibody levels. The data cast doubts on a major involvement of antibodies in virus clearance from the bloodstream within the timeframe examined.
dc.language.iso	eng
dc.relation.ispartof	Scientific Reports, 2022, vol. 12, num. 8273
dc.subject	Resposta immunitària
dc.subject	Microbiologia
dc.subject	Virus
dc.title	Combined kinetic analysis of SARS-CoV-2 RNAemia, N-antigenemia and virus-specific antibodies in critically ill adult COVID-19 patients
dc.type	journal article	es_ES
dc.date.updated	2022-06-15T17:53:11Z
dc.identifier.doi	10.1038/s41598-022-12461-5
dc.identifier.idgrec	154234
dc.rights.accessRights	open access	es_ES